Kara Cannon Net Worth

The estimated Net Worth of Kara Cannon is at least $712 Thousand dollars as of 21 February 2024. Ms. Cannon owns over 10,640 units of Enzo Biochem stock worth over $340,903 and over the last 3 years she sold ENZ stock worth over $0. In addition, she makes $371,312 as Chief Commercial Officer at Enzo Biochem.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Cannon ENZ stock SEC Form 4 insiders trading

Kara has made over 2 trades of the Enzo Biochem stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 10,640 units of ENZ stock worth $11,810 on 21 February 2024.

The largest trade she's ever made was exercising 10,640 units of Enzo Biochem stock on 21 February 2024 worth over $11,810. On average, Kara trades about 1,643 units every 73 days since 2022. As of 21 February 2024 she still owns at least 307,120 units of Enzo Biochem stock.

You can see the complete history of Ms. Cannon stock trades at the bottom of the page.

Kara Cannon biography

Kara Cannon serves as Chief Commercial Officer of the Company. She is responsible for strategic and tactical marketing, sales, manufacturing and general management of the operations. Ms. Cannon previously held executive positions at Pall Corporation, where she focused on commercial operations within the areas of diagnostics, biotechnology and biosciences. She has also held marketing and technical positions at Dynal Biotech (now ThermoFisher Scientific). She has had extensive experience in the marketing and selling of innovative platforms for the diagnostics markets, as well as the development and execution of strategic plans for the growth and sustainability of diagnostic-related businesses. Ms. Cannon holds a BA from Franklin and Marshall College.

What is the salary of Kara Cannon?

As the Chief Commercial Officer of Enzo Biochem, the total compensation of Kara Cannon at Enzo Biochem is $371,312. There are 5 executives at Enzo Biochem getting paid more, with Elazar Rabbani having the highest compensation of $1,487,800.

How old is Kara Cannon?

Kara Cannon is 52, she's been the Chief Commercial Officer of Enzo Biochem since 2018. There are 10 older and 2 younger executives at Enzo Biochem. The oldest executive at Enzo Biochem, Inc. is Dr. Elazar Rabbani Ph.D., 78, who is the Co-Founder, Chairman, Chief Scientific Officer & Sec..

What's Kara Cannon's mailing address?

Kara's mailing address filed with the SEC is C/O ENZO BIOCHEM, INC., 21 EXECUTIVE BLVD., FARMINGDALE, NY, 11735.

Insiders trading at Enzo Biochem

Over the last 22 years, insiders at Enzo Biochem have traded over $2,615,763 worth of Enzo Biochem stock and bought 1,070,494 units worth $3,103,461 . The most active insiders traders include Bradley Louis Radoff, Management Corp Harbert Dis..., and Elazar Rabbani. On average, Enzo Biochem executives and independent directors trade stock every 127 days with the average trade being worth of $59,099. The most recent stock trade was executed by Kara Cannon on 21 February 2024, trading 10,640 units of ENZ stock currently worth $11,810.

What does Enzo Biochem do?

enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.

Complete history of Ms. Cannon stock trades at Enzo Biochem

Enzo Biochem executives and stock owners

Enzo Biochem executives and other stock owners filed with the SEC include:

• Elazar Rabbani,
  Chairman of the Board, Chief Executive Officer, Secretary
• Barry Weiner,
  President, Treasurer
• Dr. Elazar Rabbani Ph.D.,
  Co-Founder, Chairman, Chief Scientific Officer & Sec.
• Barry W. Weiner,
  Founder, Treasurer & Pres
• Dieter Schapfel,
  Chief Medical Director - Enzo Clinical Labs
• Kara Cannon,
  Chief Commercial Officer
• Dr. Dieter Schapfel M.D.,
  Chief Medical Director of Enzo Clinical Labs
• David Bench,
  Chief Financial Officer, Principal Accounting Officer
• David A. Bench,
  CFO & Principal Accounting Officer
• Dov Perlysky,
  Lead Independent Director
• Rebecca Fischer,
  Independent Director
• Ian Walters,
  Independent Director
• Mary Tagliaferri,
  Independent Director
• Kara Cannon,
  Chief Commercial Officer
• Hamid Erfanian,
  CEO & Director
• Bruce A. Dey,
  VP of Sales & Marketing - Enzo Clinical Labs
• Gregory M. Bortz,
  Director
• Bernard L Kasten,
  Director
• David C Goldberg,
  VP CorpDev Pres Enz Clin Labs
• Steven J Pully,
  Director
• Bruce A. Hanna,
  Director
• James Michael O'brien,
  EVP of Finance
• Peter J Iv Clemens,
  10% owner
• Management Corp Harbert Dis...,
  
• Stanford S Warshawsky,
  Director
• Fabian Blank,
  Director
• Christine Fischette,
  Pres., Enzo Therapeutics, Inc.
• Irwin Gerson,
  Director
• John Delucca,
  Director
• Stephen B H Kent,
  Director
• Dean Engelhardt,
  Executive Vice President
• Melvin F Lazar,
  Director
• Barbara E Thalenfeld,
  VP Corporate Development
• John B Sias,
  Director
• Carl W Balezentis,
  Pres., Enzo Life Sciences
• Kevin Krenitsky,
  President, Enzo Clinical Labs
• Shahram K Rabbani,
  COO, Treasurer & Secretary
• Norman E Kelker,
  Senior Vice President
• Herbert B Bass,
  VP of Finance
• Andrew P Whiteley,
  VP BusDev-COO Enzo Lif Sci Inc
• Bradley Louis Radoff,
  Director
• James G. Wolf,
  
• Hamid Erfanian,
  Chief Executive Officer
• Patricia Eckert,
  Chief Financial Officer